Management Challenges in an Older Patient With Metastatic Renal Cell Carcinoma CME

Author Information and Disclosures

Release Date: September 30, 2008; Valid for credit through September 30, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Bayer, Onyx
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Identify unique patient factors and clinical features of renal cell carcinoma (RCC), including comorbidities and issues of prognostic importance
  2. Cite the clinical evidence regarding the efficacy of current treatment options for previously untreated patients with advanced RCC
  3. Determine the appropriate therapy for patients with advanced RCC progressing after first-line treatment as suggested by evidence-based medicine and current clinical guidelines
  4. List appropriate management of therapy-related adverse effects in patients with advanced RCC
Authors and Disclosures

Keith T. Flaherty, MD
Disclosure: Keith T. Flaherty, MD, has disclosed that he has served as an advisor or consultant to Bayer, Onyx, Pfizer, Genentech, and Wyeth.


Emma P. Hitt, PhD
Disclosure: Emma P. Hitt, PhD, has disclosed no relevant financial relationships.


Jill W. Chamberlain
Disclosure: Jill W. Chamberlain, has disclosed no relevant financial relationships.


Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.